Therapeutic approaches and outcomes in patients with larynx or hypopharynx high‐grade neuroendocrine carcinoma: A s ingle‐center retrospective analysis

Head & Neck ◽  
2021 ◽  
Author(s):  
Luana Guimaraes Sousa ◽  
Felippe Lazar Neto ◽  
Danice Karagiannis Torman ◽  
Eduardo M. Diaz ◽  
David I. Rosenthal ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Neuroendocrine Carcinoma ◽  
High Grade ◽  
Therapeutic Approaches

Radiation Therapy for High-Grade Neuroendocrine Carcinoma of the Rectum and Anal Canal

2014 ◽  
Vol 90 (1) ◽  
pp. S394
Author(s):  
K. Voong ◽  
A. Rashid ◽  
C.H. Crane ◽  
B.D. Minsky ◽  
S. Krishnan ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Anal Canal ◽  
Neuroendocrine Carcinoma ◽  
High Grade ◽  
Carcinoma Of The Rectum

scholarly journals Esophageal neuroendocrine carcinoma presenting as a rare cause of dysphagia

2018 ◽  
Vol 5 (2) ◽  
pp. 1
Author(s):  
Sylvester Luu ◽  
Brian C. Benson ◽  
Kelly A. Haeusler ◽  
Robert O. Brady ◽  
Katherine M. Cebe ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Neuroendocrine Carcinoma ◽  
Poor Prognosis ◽  
Gastroesophageal Junction ◽  
Prior History ◽  
High Grade ◽  
Active Smoking ◽  
Platinum Based Chemotherapy ◽  
History Of ◽  
Neuroendocrine Carcinomas

A 60-year-old male with prior history of laryngeal carcinoma and active smoking presented with six months of solid food dysphagia. Endoscopy showed a large, friable gastroesophageal junction mass. Biopsies revealed a high-grade, poorlydifferentiated neuroendocrine carcinoma. He was subsequently started on platinum based chemotherapy and radiation therapy and his tumor decreased dramatically in size. This case is unique as neuroendocrine carcinomas (NECs) are rarely found in the esophagus and usually have a poor prognosis at time of diagnosis.

scholarly journals Emerging Therapeutic Concepts and Latest Diagnostic Advancements Regarding Neuroendocrine Tumors of the Gynecologic Tract

Medicina ◽  
2021 ◽  
Vol 57 (12) ◽  
pp. 1338
Author(s):  
Tiberiu-Augustin Georgescu ◽  
Roxana Elena Bohiltea ◽  
Octavian Munteanu ◽  
Florentina Furtunescu ◽  
Antonia-Carmen Lisievici ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Neuroendocrine Carcinoma ◽  
Classification System ◽  
Who Classification ◽  
Small Cell ◽  
International Agency ◽  
Low Grade ◽  
High Grade ◽  
Small Cell Neuroendocrine Carcinoma ◽  
Female Genital

Neuroendocrine neoplasms (NENs) are particularly rare in all sites of the gynecological tract and include a variety of neoplasms with variable prognosis, dependent on histologic subtype and site of origin. Following the expert consensus proposal of the International Agency for Research on Cancer (IARC), the approach in the latest World Health Organization (WHO) Classification System of the Female Genital Tumours is to use the same terminology for NENs at all body sites. The main concept of this novel classification framework is to align it to all other body sites and make a clear distinction between well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). The previous WHO Classification System of the Female Genital Tumours featured more or less the same principle, but used the terms ‘low-grade neuroendocrine tumor’ and ‘high-grade neuroendocrine carcinoma’. Regardless of the terminology used, each of these two main categories include two distinct morphological subtypes: NETs are represented by typical and atypical carcinoid and NEC are represented by small cell neuroendocrine carcinoma (SCNEC) and large cell neuroendocrine carcinoma (LCNEC). High-grade NECs, especially small cell neuroendocrine carcinoma tends to be more frequent in the uterine cervix, followed by the endometrium, while low-grade NETs usually occur in the ovary. NENs of the vulva, vagina and fallopian tube are exceptionally rare, with scattered case reports in the scientific literature.

NCOG-14. REAL-WORLD RETROSPECTIVE ANALYSIS OF TUMOR TREATING FIELDS IN THE TREATMENT OF HIGH-GRADE GLIOMA BASED ON CHINESE POPULATION

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi154-vi155
Author(s):  
Lingchao Chen ◽  
Junrui Chen ◽  
Kun Song ◽  
Jingtao Nie ◽  
Dongxiao Zhuang ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Real World ◽  
Chinese Population ◽  
Adverse Reactions ◽  
High Grade Glioma ◽  
High Grade ◽  
Newly Diagnosed ◽  
Efficacy Data ◽  
Tumor Treating Fields ◽  
Recurrent Gbm

Abstract OBJECTIVES Tumor Treating Fields (TTFields) has been approved for the treatment of newly diagnosed and relapsed glioblastoma（GBM）in China in 2020. Only few TTFields data in Asia patients were reported. This retrospective analysis is aimed at investigating the efficacy, safety and the potential relationship with biomarkers of TTFields treatment in the real-world clinical practice of the Chinese glioma population. METHODS High-grade glioma patients who were under TTFields treatment from May 2019 to May 2021 in Shanghai Huashan Hospital were analyzed, including baseline data, efficacy data and incidence of adverse events. RESULTS Eighty-two patients (median age 51.0 [26.0 - 47.0] years) with high-grade glioma were enrolled, including 60 newly diagnosed GBM, 16 recurrent GBM, and 6 WHO grade III gliomas. The median time was 9.9 (4.6-15.7) months for follow-ups, median time for TTFields treatment was 4.3(1.1-20.35) months. The median compliance rate was 90% (40%-97%). For newly diagnosed GBM (n=60) and recurrent GBM (n=16), the 6-month PFS rate were 78.4% (95%CI: 63.9-87.6) and 46.7% (95%CI: 21.2- 67.8) respectively. The 10-month OS rate were 86.3% (95%CI: 69.6- 94.2) and 60.0% (95%CI: 12.6- 88.2) respectively. The 6-month PFS rate in the IDHw/TERTm population was 69.9% (95%CI: 45.9-84.9) and 78.3% (95%CI: 46.5-92.5) in the IDHw/TERTw patients with newly diagnosed GBM. 59(72%) patients had skin-related adverse reactions, and majority are grade 1-2 (grade 1-2, 69.5%; grade 3, 2.5%). CONCLUSIONS This is the 1st retrospective analysis done using TTFields in the treatment of high-grade gliomas in the Chinese population with the largest sample size. From our short follow up, TTFields appears good efficacy among GBM patients. The incidence of skin adverse reactions is higher comparable to published data, but mainly consisted of grade1-2. Long-term efficacy data need to be further followed-up.

Sign in / Sign up

Export Citation Format

Share Document